Former Chairman of the Board and Chief Executive Officer, Allergan
David Pyott MSc13(1980) joined Allergan from Novartis in 1998 as CEO and spent the next 17 years turning the small eye care company into a global bio-pharmaceutical player. He increased sales from US$1.1 billion on his arrival to $7.1 billion in 2014 by innovation and by diversifying into specialist treatments such as Botox. In 2015, Pyott stepped down as chief executive when Allergan was sold to Actavis for $71 billion.
Pyott is Lead Director and a member of the Board of Directors of Avery Dennison Corporation, a member of the Boards of Alnylam Pharmaceuticals Inc. and BioMarin Pharmaceutical Inc., a member of the Supervisory Board of Royal Philips in the Netherlands, Chairman of Bioniz Therapeutics and President of the International Council of Ophthalmology Foundation. He is involved on the boards of many other US and international eye care charities as well as a member of London Business School’s Governing Body.
In 2006, Pyott was bestowed the honour of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen. In addition to his MSc from London Business School, he holds a diploma in German and European Law from the Europa Institute at the University of Amsterdam, an MA and an Honorary Degree in Medicine from the University of Edinburgh.
From dealing with financial crises to fending off a hostile takeover bid, these chief executives have seen it all. Here, they share their greatest challenges and biggest business lessons.
David Pyott, alumnus and member of the School’s Governing Body, has made a landmark gift to its comprehensive £100million fundraising campaign.
Professor Randall S Peterson talks to David Pyott, former Allergan CEO, about the takeover of the global pharmaceuticals company he helped to build.
David Pyott was the chairman and CEO of the global healthcare company Allergan.